Lung cancer gene therapy

Abbreviations: small cell lung cancer (SCLC); non-small cell lung cancer (NSCLC); intratumoral injection of Ad-p53 (INGN 201); murine double minute-2 (MDM2); cisplatin (CDDP); active metabolite of irinotecan (CPT-11); O(6)-methylguanine-DNA methyltransferase (MGMT); retinoblastoma (RB); fragile histidine triad (FHIT); tumor necrosis factor-related apoptosis-inducing ligand (TRAIL); triplex forming oligonucleotides (TFO); melanoma differentiation associated gene-7 (mda-7); carcinoembryonic antigen (CEA); replication-deficient adenovirus vector, Ad-mda7 (INGN 241); MAPK-activated kinases (Rsks); ). Insulin-like growth factor binding proteins (IGFBPs); cyclooxygenase (COX)-2; ganglioside G(D2); Herpes simplex virus 1 (HSV); thymidine kinase (tk); ganciclovir (GCV); gastrin-releasing peptide (GRP); neuron specific enolase (NSE); Cre recombinase(Cre)/loxP; hypoxanthine-guanine phosphoribosyl transferase (HGPRT); Trypanosoma brucei (Tb); sodium iodide symporter (NIS); thyroperoxidase (TPO); matrix metalloproteinase (MMP); secret form of human platelet facter 4 (Spf4); vascular endothelial growth factor (VEGF); soluble flt-1 (sFLT1); Tie2-expressing mononuclear (TEM); dendritic cells (DCs); Lewis lung carcinoma (LLC); natural killer (NK) cells; tumor necrosis factor receptor (TNF-R); 1,3) Galactosyl epitopes (·Gal); proliferin-related protein (PRP); interferon-inducible protein 10 (IP10); interferon (IFN)